|
GM. This is The Financial Darwin Awards, rounding up the internet's biggest Ls so you don't make them yourself. Wednesday was a day about who gets to decide. The Bancorp closed down 22.33% because of an acquisition it was not part of. Tyra Biosciences fell 17.66% on trial data that worked. Three people lost $66,208 between them. Each of them owned the asset and rented the decision. The traders are composites. The moves are not. Here's what we've got today:
THIS WEEK'S DAMAGE REPORT 📊
The first number is the sum of the three stories below. The second is real: the 10-year Treasury yield closed Wednesday at 4.843%, up 3.9 basis points and a fresh 52-week high, with Brent crude above $101.
DARWIN AWARD OF THE WEEK 🏆 Every issue we crown the single worst financial decision on the internet. This week it goes to a man who owned the plumbing and forgot who signed off the plumbing budget. Here's the setup. u/they_need_our_charter owned 2,300 shares of The Bancorp, about $148,143, at Tuesday's close of $64.41. The Bancorp is one of a handful of companies that rent their banking licence to fintech apps. His thesis was that this is infrastructure, and infrastructure is sticky. A fintech cannot just become a chartered bank. One problem: it does not have to become one. It can buy one. On Tuesday Chime agreed to acquire Stride Bank for $590 million in cash, giving it a nationally chartered bank subsidiary of its own. Chime ran on two partners, Stride and The Bancorp, and had used Stride for more than seven years. It plans to consolidate its banking activity under Stride once the deal closes in the first half of 2027, expecting more than $100 million in net synergies. Read that last figure for what it is. Those synergies are somebody else's fee revenue. The Bancorp closed Wednesday at $50.03, down $14.38, or 22.33%. 2,300 shares, down $14.38 each, is $33,074. He thought he owned a moat. He owned a line item on his customer's cost sheet.
Here's the thing. Being essential to one customer is not a moat, it is a make-or-buy decision sitting on somebody else's whiteboard. That is the part worth understanding, and it cost him $33,074 to learn that a switching cost is only high until someone prices the switch.
THIS WEEK'S CASUALTIES 💀 Not everybody can be Darwin Award of the week. These two were right about the asset and wrong about the decider. Casualty #1: The Man Whose Drug Worked u/my_drug_worked owned 4,400 shares of Tyra Biosciences, about $117,612, at $26.73. Tyra's lead candidate, dabogratinib, reported initial Phase 2 data from the SURF302 study in bladder cancer on Wednesday. The data worked. At the 60mg once-daily dose, 11 of 14 patients responded, a 79% overall response rate, and 9 of them reached a complete response. So he was right about the biology. He was wrong about the one number being priced. Piper Sandler and H.C. Wainwright had both set the bar at a 70% complete response rate at three months. Tyra's own release puts the three-month complete response rate at 57%, which is 8 of those 14 patients. One more complete responder would have made it 10 of 14, or 71%, and cleared the bar. Tyra closed at $22.01, down $4.72, or 17.66%. 4,400 shares, down $4.72 each, is $20,768.
Here's the thing. Clinical-stage biotech does not trade on whether a drug works, it trades on the gap between the readout and the number analysts wrote down beforehand. That is the part worth understanding, and it cost him $20,768 to learn that a good result and a beat are two different events.
Casualty #2: The Man Waiting On The Appeal u/appeals_are_free was long 1,800 Booking Holdings shares, about $324,540, at Tuesday's close of $180.30. Part of what he was paying for was an old deal. In 2023 the European Commission blocked Booking's roughly 1.63 billion euro acquisition of the flight-booking group ETraveli, and Booking appealed. Three years of litigation read to him as confidence. Nobody spends three years defending a case they expect to lose. On Wednesday the EU's General Court in Luxembourg upheld the Commission. The judges found the Commission had correctly concluded the deal would have strengthened Booking's already dominant position among online travel agencies. Booking said it disagrees and is reviewing a possible appeal to the European Court of Justice. Booking closed Wednesday at $173.43, down $6.87, or 3.81%, after trading as low as $170.12. 1,800 shares, down $6.87 each, is $12,366.
Here's the thing. A pending appeal is an option with no premium quoted and no expiry printed, which is exactly why it feels free and gets held forever. That is the part worth understanding, and it cost him $12,366 to learn that the length of a case measures the docket, not the merits.
THIS WEEK BY THE NUMBERS 📊 We track the data because the data is funnier than anything we could make up.
The Russell 2000 closed down 1.36%, the worst of the major indexes, against the Dow at -0.77% and the S&P 500 at -0.48%. Two of the three held small caps on the day small caps led the way down.
BITE-SIZED COPIUM FOR THE ROAD 🍪 The best part of any loss thread is the comments.
Translation: three true statements, none of them about the thing being priced.
DUMB MEMES 🤣 Ours hits different when you were right about the asset.
POV: your largest client reads your invoice as a savings target
u/my_drug_worked, right about the medicine If you laughed, you're coping. If you didn't, go and work out who has to agree for your largest position to work. See you next issue. Three real assets. Three other people deciding. Traders and P&L screenshots are satirical composites. Market data, court rulings, trial results and price moves are real and dated September 9, 2026. Not financial advice. Obviously. Stay liquid, |
All three owned the asset. Somebody else owned the decision.
The Bancorp fell 22.33% because its own customer bought a bank charter, Tyra fell 17.66% because one patient in fourteen went the wrong way, and a man who held Booking for a three-year appeal lost it in one afternoon in Luxembourg.
